Vernalis interims confirm that first sales of Tuzistra® XR (the company’s lead long-acting prescription cough cold medicine) have been impacted by an unusually mild US flu season, with net sales of £0.6m during the period. Operating loss has widened YoY from £(4.3)m to £(13.5)m principally as a result of the significant costs associated with the launch and promotion of Tuzistra® XR in the USA, whilst R&D costs have reduced as a result of a planned scaledown of drug development activity. We will ....
